These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 7344512)

  • 1. Metabolic activation of triazene cytostatics.
    Kolar GF; Wildschütte M
    Adv Exp Med Biol; 1981; 136 Pt B():1285-96. PubMed ID: 7344512
    [No Abstract]   [Full Text] [Related]  

  • 2. Triazene metabolism. IV. Derivatives of hydroxymethyltriazenes: potential prodrugs for the active metabolites of the anti-tumour triazene, DTIC.
    Cameron LM; LaFrance RJ; Hemens CM; Vaughan K; Rajaraman R; Chubb DC; Goddard PM
    Anticancer Drug Des; 1985 Oct; 1(1):27-36. PubMed ID: 3870878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacobiochemistry of arylalkyltriazenes and their application in cancer chemotherapy.
    Spassova MK; Golovinsky EV
    Pharmacol Ther; 1985; 27(3):333-52. PubMed ID: 3901047
    [No Abstract]   [Full Text] [Related]  

  • 4. The metabolism of triazene antitumor drugs.
    Gescher A; Threadgill MD
    Pharmacol Ther; 1987; 32(2):191-205. PubMed ID: 3299401
    [No Abstract]   [Full Text] [Related]  

  • 5. Experimental intraocular penetration of dacarbazine.
    Wilczek ZM
    Am J Ophthalmol; 1977 Sep; 84(3):299-304. PubMed ID: 409297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dimethyltriazenes on in vitro Lewis lung carcinoma tumor lines with different metastatic capacity.
    Zupi G; Corsi A; Sacchi A; Lassiani L; Giraldi T
    Invasion Metastasis; 1984; 4(3):179-88. PubMed ID: 6480290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutagenicity of dimethyl heteroaromatic triazenes in the Ames test: the role of hydrophobicity and electronic effects.
    Shusterman AJ; Debnath AK; Hansch C; Horn GW; Fronczek FR; Greene AC; Watkins SF
    Mol Pharmacol; 1989 Dec; 36(6):939-44. PubMed ID: 2601689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinogenicity of cytostatic triazenes.
    Kolar GF
    IARC Sci Publ; 1986; (78):111-26. PubMed ID: 3583385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Observations on the "in vitro" oxidative N-demethylation of 4-(3, 3-dimethyl-1-triazeno)-imidazole-5-carboxamide (DIC, NSC 45388).
    Giraldi T; Nisi C; Sava G
    Pharmacol Res Commun; 1976 Feb; 8(1):25-9. PubMed ID: 1026951
    [No Abstract]   [Full Text] [Related]  

  • 10. Oxidative metabolism of 1-(2-chloroethyl)-3-alkyl-3- (methylcarbamoyl)triazenes: formation of chloroacetaldehyde and relevance to biological activity.
    Rouzer CA; Sabourin M; Skinner TL; Thompson EJ; Wood TO; Chmurny GN; Klose JR; Roman JM; Smith RH; Michejda CJ
    Chem Res Toxicol; 1996; 9(1):172-8. PubMed ID: 8924588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimetastatic action of some triazene derivatives against the Lewis lung carcinoma in mice.
    Giraldi T; Houghton PJ; Taylor DM; Nisi C
    Cancer Treat Rep; 1978 May; 62(5):721-5. PubMed ID: 657157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of DTIC (NSC-45388) in animals.
    Venditti JM
    Cancer Treat Rep; 1976 Feb; 60(2):135-40. PubMed ID: 1260771
    [No Abstract]   [Full Text] [Related]  

  • 13. Stochastic compartmental modeling of the disposition of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).
    McInnis B; Kapadia A; El-Asfouri S; Loo TL
    Cancer Chemother Rep; 1975; 59(4):843-5. PubMed ID: 1175174
    [No Abstract]   [Full Text] [Related]  

  • 14. Studies of the mode of action of antitumour triazenes and triazines-II. Investigation of the selective toxicity of 1-aryl-3,3-dimethyltriazenes.
    Gescher A; Hickman JA; Simmonds RJ; Stevens MF; Vaughan K
    Biochem Pharmacol; 1981 Jan; 30(1):89-93. PubMed ID: 7213416
    [No Abstract]   [Full Text] [Related]  

  • 15. Functional-group modifications of dextran for linkage to a diazonium group. A potential vehicle for tumour targeting of antineoplastic triazenes.
    Baki AV; Vaughan K
    Carbohydr Res; 1982 Jul; 105(1):57-68. PubMed ID: 6180830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proceedings: Chemical mechanisms and biotransformations involved in triazene mutagenesis.
    Kolar GF
    Mutat Res; 1975 Aug; 29(2):236-7. PubMed ID: 1186741
    [No Abstract]   [Full Text] [Related]  

  • 17. Triazene metabolism. III. In vitro cytotoxicity towards M21 cells and in vivo antitumour activity of the proposed metabolites of the antitumour 1-aryl-3,3-dimethyltriazenes.
    Kohlsmith DJ; Vaughan K; Luner SJ
    Can J Physiol Pharmacol; 1984 Apr; 62(4):396-402. PubMed ID: 6733585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of the mode of action of antitumour triazenes and triazines--IV. The metabolism of 1-(4-acetylphenyl)-3,3-dimethyltriazene.
    Farina P; Gescher A; Hickman JA; Horton JK; D'Incalci M; Ross D; Stevens MF; Torti L
    Biochem Pharmacol; 1982 May; 31(10):1887-92. PubMed ID: 7104021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental studies at Southern Research Institute with DTIC (NSC-45388).
    Montgomery JA
    Cancer Treat Rep; 1976 Feb; 60(2):125-34. PubMed ID: 1260770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Carcinostatics based on 1-phenyl-3,3-dimethyl triazene. IV. Kinetics and proteolytic cleavage].
    Matrka M; Rambousek V; Zvĕrina V
    Cesk Farm; 1978 Oct; 27(8):346-9. PubMed ID: 743752
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.